First Trust NYSE Arca Biotechnology Index Fund
FBTDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 31, 2024 | $1.17 | 2024-12-13 | 2024-12-13 |
| September 30, 2015 | $0.02 | 2015-09-23 | 2015-09-25 |
| June 30, 2015 | $0.06 | 2015-06-24 | 2015-06-26 |
| March 31, 2015 | $0.05 | 2015-03-25 | 2015-03-27 |
| December 31, 2014 | $0.05 | 2014-12-23 | 2014-12-26 |
Dividends Summary
- Consistent Payer: First Trust NYSE Arca Biotechnology Index Fund has rewarded shareholders with 6 dividend payments over the past 16 years.
- Total Returned Value: Investors who held FBT shares during this period received a total of $1.63 per share in dividend income.
- Latest Payout: The most recent dividend of $1.17/share was paid 564 days ago, on December 31, 2024.
- Yield & Schedule: FBT currently pays dividends quarterly with an annual yield of 0.53%.
- Dividend Growth: Since 2008, the dividend payout has grown by 334.8%, from $0.27 to $1.17.
Company News
First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%...
The article compares two healthcare-focused ETFs: Invesco Pharmaceuticals ETF (PJP) and First Trust NYSE Arca Biotechnology Index Fund (FBT). PJP focuses on established pharmaceutical companies with lower volatility and dividend income, while FBT targets high-growth biotech stocks with greater exposure to small and mid-cap companies. Despite FBT'...
The article compares two healthcare-focused ETFs: State Street SPDR S&P Pharmaceuticals (XPH) and First Trust NYSE Arca Biotechnology Index Fund (FBT). XPH offers lower costs (0.35% expense ratio vs 0.55%), broader diversification with 59 holdings, and better 1-year performance (38% vs 35.90%), plus dividend income. FBT provides more concentrated...
The FDA has reversed its previous refusal-to-file decision and accepted Moderna's biologics license application for mRNA-1010, an mRNA-based flu vaccine for adults 50 and older, with an August 5 PDUFA goal date. The stock surged 5.77% on the news. Moderna also beat Q4 earnings expectations with a smaller loss and higher-than-expected revenue of $...
The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange-traded fund that provides broad exposure to the healthcare-biotech sector. The ETF tracks the NYSE Arca Biotechnology Index and has a relatively high expense ratio of 0.56%. Its top holdings include Alnylam Pharmaceuticals, Corcept Therapeutics, and United Therapeut...
